Cell Therapy News/Articles, page-16894

You weren’t correct … technically or otherwise - you know it and I know it but whatever makes you feel good lol


As for the Oaktree facility - I am guessing that ship has already sailed given the 30th Sept has come and gone without an announcement from Mesoblast ? I don’t know this for a fact but based on the last extension in Dec 2022 Mesoblast told the market 8 days prior to the original expiry date of 31 Dec 2022. This time around we have heard nothing and we have now entered October ? Perhaps Mesoblast are closer to a license deal or partnership deal than we think or perhaps Oaktree said no to the extension ? I guess we will find out when they tell us


Melbourne, Australia; December 23 and New York, USA; December 22, 2022: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that funds managed by Oaktree Capital Management, L.P. (“Oaktree” have extended to Mesoblast the availability of up to an additional US$30.0 million of its US$90 million five year facility subject to achieving certain milestones on or before September 30, 2023.




Melbourne, Australia; November 22, and New York, USA; November 21, 2021: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has successfully refinanced its existing senior debt facility with a new US$90 million five year facility provided by funds managed by Oaktree Capital Management, L.P. (“Oaktree”.

Mesoblast drew the first tranche of US$60 million on closing, with proceeds being used to repay the outstanding balance of the existing senior debt facility with Hercules Capital, Inc. Up to an additional US$30 million may be drawn on or before December 31, 2022, subject to certain milestones. The facility has a three-year interest only period, at a rate of 9.75% per annum, after which time 40% of the principal amortizes over two years and a final payment due November 2026. Oaktree will also receive warrants to purchase 1,769,669 American Depositary Shares (ADSs)1 at US$7.26 per ADS, a 15% premium to the 30-day VWAP. The warrants may be exercised within 7 years of issuance.